Monique M Ryan

List of Publications by Year
in descending order

145 papers	6,028 citations	87843 38 h-index	85498 71 g-index
147 all docs	147 docs citations	147 times ranked	8063 citing authors

#	Article	IF	Citations
1	Guillainâ€“BarrÃ© syndrome with optic neuritis. Journal of Paediatrics and Child Health, 2022, 58, 887-890.	0.4	3
2	Gene therapy for neuromuscular disorders: prospects and ethics. Archives of Disease in Childhood, 2022, 107, 421-426.	1.0	3
3	Biallelic Variants in PYROXD2 Cause a Severe Infantile Metabolic Disorder Affecting Mitochondrial Function. International Journal of Molecular Sciences, 2022, 23, 986.	1.8	5
4	The association between dietary factors and body weight and composition in boys with Duchenne muscular dystrophy. Journal of Human Nutrition and Dietetics, 2022, 35, 804-815.	1.3	3
5	Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 530-538.	0.9	10
6	Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Annals of Clinical and Translational Neurology, 2022, 9, 339-350.	1.7	32
7	Delivering multidisciplinary neuromuscular care for children via telehealth. Muscle and Nerve, 2022, 66, 31-38.	1.0	7
8	Scientific rationale for a higher dose of nusinersen. Annals of Clinical and Translational Neurology, 2022, 9, 819-829.	1.7	9
9	The effects of calf massage in boys with Duchenne muscular dystrophy: a prospective interventional study. Disability and Rehabilitation, 2021, 43, 3803-3809.	0.9	5
10	Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes. Disability and Rehabilitation: Assistive Technology, 2021, 16, 880-889.	1.3	9
11	Pathogenic deep intronic MTM1 variant activates a pseudo-exon encoding a nonsense codon resulting in severe X-linked myotubular myopathy. European Journal of Human Genetics, 2021, 29, 61-66.	1.4	10
12	The severe epilepsy syndromes of infancy: A populationâ€based study. Epilepsia, 2021, 62, 358-370.	2.6	31
13	International retrospective natural history study of LMNA-related congenital muscular dystrophy. Brain Communications, 2021, 3, fcab075.	1.5	17
14	Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial. Clinical Nutrition, 2021, 40, 4702-4711.	2.3	4
15	Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient. Stem Cell Research, 2021, 54, 102429.	0.3	3
16	Comment on: Paediatric Facial Paralysis: An overview and Insights into Management. Journal of Paediatrics and Child Health, 2021, 57, 1725-1725.	0.4	0
17	Characterising gait in paediatric neuromuscular disorders: an observational study of spatio-temporal gait in a clinical cohort. Disability and Rehabilitation, 2021, , 1-7.	0.9	0
18	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Journal of Neuromuscular Diseases, 2021, 8, 769-784.	1.1	13

#	Article	IF	Citations
19	Cerebellar ataxia with normal intellect associated with a homozygous truncating variant in CA8. Clinical Genetics, 2020, 97, 516-520.	1.0	2
20	Efficacy and safety of vamorolone in Duchenne muscular dystrophy:ÂAn 18-month interim analysis of a non-randomized open-label extension study. PLoS Medicine, 2020, 17, e1003222.	3.9	41
21	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	0.6	41
22	NEMF mutations that impair ribosome-associated quality control are associated with neuromuscular disease. Nature Communications, 2020, 11, 4625.	5.8	47
23	Cardiac phenotype in ATP1A3 -related syndromes. Neurology, 2020, 95, e2866-e2879.	1.5	19
24	Communication about spinal muscular atrophy and genetic risk within families: An Australian pilot study. Journal of Paediatrics and Child Health, 2020, 56, 1263-1269.	0.4	3
25	Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Scientific Reports, 2020, 10, 9262.	1.6	15
26	Distinct effects on mRNA export factor GANP underlie neurological disease phenotypes and alter gene expression depending on intron content. Human Molecular Genetics, 2020, 29, 1426-1439.	1.4	4
27	Benefits of powered standing wheelchair devices for adolescents with Duchenne muscular dystrophy in the first year of use. Journal of Paediatrics and Child Health, 2020, 56, 1419-1425.	0.4	10
28	242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1â€“3 March 2019. Neuromuscular Disorders, 2020, 30, 254-264.	0.3	12
29	Neuronal ceroid lipofuscinosis type 2: an Australian case series. Journal of Paediatrics and Child Health, 2020, 56, 1210-1218.	0.4	19
30	A homozygous UBA5 pathogenic variant causes a fatal congenital neuropathy. Journal of Medical Genetics, 2020, 57, 835-842.	1.5	16
31	Falls in paediatric Charcot-Marie-Tooth disease: a 6-month prospective cohort study. Archives of Disease in Childhood, 2019, 104, 535-540.	1.0	10
32	Peripheral nerve disease secondary to systemic conditions in children. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641986636.	1.5	4
33	Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Frontiers in Neurology, 2019, 10, 898.	1.1	49
34	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 2019, 29, 842-856.	0.3	401
35	Importance of muscle biopsy to establish pathogenicity of DMD missense and splice variants. Neuromuscular Disorders, 2019, 29, 913-919.	0.3	19
36	Physical activity of children and adolescents with Charcot-Marie-Tooth neuropathies: A cross-sectional case-controlled study. PLoS ONE, 2019, 14, e0209628.	1.1	11

#	Article	IF	Citations
37	Neurofilament as a potential biomarker for spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 932-944.	1.7	137
38	Recessive MYH7-related myopathy in two families. Neuromuscular Disorders, 2019, 29, 456-467.	0.3	14
39	Powered standing wheelchairs promote independence, health and community involvement in adolescents with Duchenne muscular dystrophy. Neuromuscular Disorders, 2019, 29, 221-230.	0.3	16
40	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.5	64
41	Dejerineâ€“Sottas disease in childhoodâ€”Genetic and sonographic heterogeneity. Brain and Behavior, 2018, 8, e00919.	1.0	7
42	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	2.8	93
43	Unique clinical and neurophysiologic profile of a cohort of children with CMTX3. Neurology, 2018, 90, e1706-e1710.	1.5	3
44	DCC Is Required for the Development of Nociceptive Topognosis in Mice and Humans. Cell Reports, 2018, 22, 1105-1114.	2.9	21
45	Gait and footwear in children and adolescents with Charcot-Marie-Tooth disease: A cross-sectional, case-controlled study. Gait and Posture, 2018, 62, 262-267.	0.6	13
46	Investigation of the activation of the temporalis and masseter muscles in voluntary and spontaneous smile production. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2018, 71, 1051-1057.	0.5	5
47	A multinational study on motor function in early-onset FSHD. Neurology, 2018, 90, e1333-e1338.	1.5	17
48	Nusinersen for SMA: expanded access programme. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 937-942.	0.9	46
49	Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome. Seminars in Pediatric Neurology, 2018, 26, 2-9.	1.0	24
50	Evaluation of Serial Casting for Boys with Duchenne Muscular Dystrophy: A Case Report. Physical and Occupational Therapy in Pediatrics, 2018, 38, 88-96.	0.8	4
51	Infantile-Onset Myelin Protein Zeroâ€“Related Demyelinating Neuropathy Presenting as an Upper Extremity Monoplegia. Seminars in Pediatric Neurology, 2018, 26, 52-55.	1.0	3
52	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet, The, 2018, 391, 451-461.	6.3	306
53	Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. Brain, 2018, 141, 3319-3330.	3.7	25
54	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	3.1	69

#	Article	IF	Citations
55	Can in-the-moment diary methods measure health-related quality of life in Duchenne muscular dystrophy?. Quality of Life Research, 2017, 26, 1145-1152.	1.5	8
56	Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy. Annals of Clinical and Translational Neurology, 2017, 4, 318-325.	1.7	36
57	Deterioration in gait and functional ambulation in children and adolescents with Charcotâ€“Marieâ€“Tooth disease over 12 months. Neuromuscular Disorders, 2017, 27, 658-666.	0.3	19
58	MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain, 2017, 140, 2093-2103.	3.7	31
59	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	6.3	365
60	Therapeutic Options to Improve Bone Health Outcomes in Duchenne Muscular Dystrophy: Zoledronic Acid and Pubertal Induction. Journal of Paediatrics and Child Health, 2017, 53, 1247-1248.	0.4	7
61	Authors' Response to Commentary. Journal of Pediatric Rehabilitation Medicine, 2016, 9, 77.	0.3	0
62	Cerebral palsy is not a diagnosis: A case report of a novel atlastinâ€1 mutation. Journal of Paediatrics and Child Health, 2016, 52, 669-671.	0.4	5
63	Pathogenic mechanisms underlying X-linked Charcot-Marie-Tooth neuropathy (CMTX6) in patients with a pyruvate dehydrogenase kinase 3 mutation. Neurobiology of Disease, 2016, 94, 237-244.	2.1	12
64	Physical activity and the use of standard and complementary therapies in Duchenne and Becker muscular dystrophies. Journal of Pediatric Rehabilitation Medicine, 2016, 9, 55-63.	0.3	10
65	Describing nutrition in spinal muscular atrophy: A systematic review. Neuromuscular Disorders, 2016, 26, 395-404.	0.3	35
66	â€˜A short time but a lovely little short timeâ€™: Bereaved parents' experiences of having a child with spinal muscular atrophy type 1. Journal of Paediatrics and Child Health, 2016, 52, 40-46.	0.4	32
67	Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain, 2016, 139, 2877-2890.	3.7	74
68	Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. Mitochondrion, 2016, 30, 162-167.	1.6	13
69	Fifty years of paediatric neurology in Australasia. Journal of Paediatrics and Child Health, 2016, 52, 861-864.	0.4	0
70	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.3	7
71	EPG5-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. Brain, 2016, 139, 765-781.	3.7	99
72	Neurologic Melioidosis: Case Report of a Rare Cause of Acute Flaccid Paralysis. Journal of Pediatrics, 2016, 170, 319-321.	0.9	2

#	Article	IF	Citations
73	A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genetics in Medicine, 2016, 18, 1090-1096.	1.1	332
74	Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3. PLoS Genetics, 2016, 12, e1006177.	1.5	20
75	Complete callosal agenesis, pontocerebellar hypoplasia, and axonal neuropathy due to AMPD2 loss. Neurology: Genetics, 2015, 1, e16.	0.9	29
76	Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth. Orphanet Journal of Rare Diseases, 2015, 10, 148.	1.2	94
77	Strong Correlation Between the 6-Minute Walk Test and Accelerometry Functional Outcomes in Boys With Duchenne Muscular Dystrophy. Journal of Child Neurology, 2015, 30, 357-363.	0.7	22
78	Unraveling the pathogenesis of ARX polyalanine tract variants using a clinical and molecular interfacing approach. Molecular Genetics & Genomic Medicine, 2015, 3, 203-214.	0.6	21
79	A diagnostic approach to recurrent myalgia and rhabdomyolysis in children. Archives of Disease in Childhood, 2015, 100, 793-797.	1.0	29
80	Peripheral nerve ultrasound in pediatric Charcot-Marie-Tooth disease type 1A. Neurology, 2015, 84, 569-574.	1.5	42
81	A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. European Journal of Human Genetics, 2015, 23, 1294-1300.	1.4	39
82	Mononeuropathies. , 2015, , 243-273.		0
83	Acute Polyneuropathies. , 2015, , 379-397.		0
84	Disorders of the Ocular Motor Cranial Nerves and Extraocular Muscles. , 2015, , 922-957.		0
85	An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Journal of Neurology, 2015, 262, 1344-1353.	1.8	89
86	X-linked Recessive Distal Myopathy With Hypertrophic Cardiomyopathy Caused by a Novel Mutation in the FHL1 Gene. Journal of Child Neurology, 2015, 30, 1211-1217.	0.7	12
87	Overview of Pediatric Peripheral Neuropathies. , 2015, , 274-288.		2
88	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	1.0	357
89	Childhood Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Child Neurology, 2014, 29, 43-48.	0.7	19
90	De Novo Truncating Mutations in AHDC1 in Individuals with Syndromic Expressive Language Delay, Hypotonia, and Sleep Apnea. American Journal of Human Genetics, 2014, 94, 784-789.	2.6	57

#	Article	IF	Citations
91	Neuromuscular complications of intensive care. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1481-1483.	1.0	5
92	Juvenile Parkinsonism. Journal of Paediatrics and Child Health, 2013, 49, 409-411.	0.4	3
93	High resolution chromosomal microarray in undiagnosed neurological disorders. Journal of Paediatrics and Child Health, 2013, 49, 716-724.	0.4	18
94	Natural history of pulmonary function in collagen VI-related myopathies. Brain, 2013, 136, 3625-3633.	3.7	85
95	Pontocerebellar hypoplasia type 1. Neurology, 2013, 80, 438-446.	1.5	84
96	Pediatric Guillain-BarrÃ© syndrome. Current Opinion in Pediatrics, 2013, 25, 689-693.	1.0	53
97	A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene. Human Molecular Genetics, 2013, 22, 1404-1416.	1.4	64
98	Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nature Genetics, 2012, 44, 704-708.	9.4	216
99	Auditory function in children with Charcot-Marie-Tooth disease. Brain, 2012, 135, 1412-1422.	3.7	63
100	Genetic axonal neuropathies and neuronopathies of preâ€natal and infantile onset. Journal of the Peripheral Nervous System, 2012, 17, 285-300.	1.4	26
101	VENLAFAXINE INGESTION IN A 4â€YEARâ€OLD GIRL. Journal of Paediatrics and Child Health, 2012, 48, 1047-1048.	0.4	1
102	Autoimmune myasthenia gravis, immunotherapy and thymectomy in children. Neuromuscular Disorders, 2012, 22, 118-121.	0.3	16
103	A family with 2 X-linked disorders: Charcot-Marie-Tooth disease and hemophilia A. Muscle and Nerve, 2012, 46, 454-455.	1.0	1
104	Demyelinating prenatal and infantile developmental neuropathies. Journal of the Peripheral Nervous System, 2012, 17, 32-52.	1.4	14
105	Health status of boys with Duchenne muscular dystrophy: A parent's perspective. Journal of Paediatrics and Child Health, 2011, 47, 557-562.	0.4	27
106	Extended treatment of childhood Charcotâ€Marieâ€Tooth disease with highâ€dose ascorbic acid. Journal of the Peripheral Nervous System, 2011, 16, 272-274.	1.4	5
107	Pediatric sciatic neuropathy associated with neoplasms. Muscle and Nerve, 2011, 43, 183-188.	1.0	12
108	Epidermolysis bullosa with lateâ€onset muscular dystrophy and plectin deficiency. Muscle and Nerve, 2011, 44, 135-141.	1.0	16

#	Article	IF	Citations
109	Spontaneous Intracranial Hypotension in Childhood: A Case Report and Review of the Literature. Journal of Child Neurology, 2011, 26, 761-766.	0.7	5
110	Carpal Tunnel Syndrome Secondary to Ganglion Cyst in a Child. Journal of Child Neurology, 2011, 26, 630-633.	0.7	5
111	Muscle cramp in pediatric Charcot-Marie-Tooth disease type 1A. Neurology, 2011, 77, 2115-2118.	1.5	10
112	Atypical Silverâ€“Russell phenotype resulting from maternal uniparental disomy of chromosome 7. American Journal of Medical Genetics, Part A, 2010, 152A, 2342-2345.	0.7	14
113	Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric charcotâ€“marieâ€“tooth disease type 1A. Muscle and Nerve, 2010, 42, 262-267.	1.0	24
114	Atypical childhood chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2010, 42, 293-295.	1.0	7
115	Neurophysiologic findings in children presenting with pes cavus. Journal of the Peripheral Nervous System, 2010, 15, 238-240.	1.4	4
116	Respiration-Related Laryngeal Electromyography in Children with Bilateral Vocal Fold Paralysis. Annals of Otology, Rhinology and Laryngology, 2010, 119, 791-795.	0.6	5
117	Health-related Quality of Life in Boys With Duchenne Muscular Dystrophy: Agreement Between Parents and Their Sons. Journal of Child Neurology, 2010, 25, 1188-1194.	0.7	55
118	Pathophysiological Mechanisms of Dominant and Recessive GLRA1 Mutations in Hyperekplexia. Journal of Neuroscience, 2010, 30, 9612-9620.	1.7	112
119	Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain, 2010, 133, 1810-1822.	3.7	268
120	Quality of Life in Children With Charcot-Marie-Tooth Disease. Journal of Child Neurology, 2010, 25, 343-347.	0.7	21
121	Feasibility of a Computerized Method to Measure Quality of â€œEverydayâ€•Life in Children with Neuromuscular Disorders. Physical and Occupational Therapy in Pediatrics, 2010, 30, 43-53.	0.8	13
122	Ascorbic acid for Charcotâ€“Marieâ€“Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurology, The, 2009, 8, 537-544.	4.9	131
123	Evolution of foot and ankle manifestations in children with CMT1A. Muscle and Nerve, 2009, 39, 158-166.	1.0	96
124	Paralysis and a perihilar protuberance: An unusual presentation of sarcoidosis in a child. Pediatric Pulmonology, 2009, 44, 410-414.	1.0	31
125	Juvenile polymyositis or paediatric muscular dystrophy: a detailed reâ€analysis of 13 cases. Histopathology, 2009, 55, 452-462.	1.6	12
126	Acute Transverse Myelitis and Acute Disseminated Encephalomyelitis in Childhood: Spectrum or Separate Entities?. Journal of Child Neurology, 2009, 24, 287-296.	0.7	46

#	Article	IF	Citations
127	Effect of Oral Curcumin on DÃ©jÃ©rine-Sottas Disease. Pediatric Neurology, 2009, 41, 305-308.	1.0	35
128	Reliability of quantifying foot and ankle muscle strength in very young children. Muscle and Nerve, 2008, 37, 626-631.	1.0	36
129	Neurophysiologic abnormalities in children with Charcotâ€Marieâ€Tooth disease type 1A. Journal of the Peripheral Nervous System, 2008, 13, 236-241.	1.4	49
130	Hand involvement in children with Charcotâ€“Marie-Tooth disease type 1A. Neuromuscular Disorders, 2008, 18, 970-973.	0.3	44
131	The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatric Respiratory Reviews, 2008, 9, 51-54.	1.2	44
132	Dietary L-Tyrosine Supplementation in Nemaline Myopathy. Journal of Child Neurology, 2008, 23, 609-613.	0.7	58
133	Histopathological Findings in Hereditary Motor and Sensory Neuropathy of Axonal Type With Onset in Early Childhood Associated WithMitofusin 2Mutations. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1097-1102.	0.9	81
134	Gaining consent for publication in difficult cases involving children. BMJ: British Medical Journal, 2008, 337, a1231-a1231.	2.4	10
135	Critical illness polyneuropathy and myopathy in pediatric intensive care: A review. Pediatric Critical Care Medicine, 2007, 8, 18-22.	0.2	75
136	Establishment of the Australasian paediatric Charcot-Marie-Tooth disease registry. Neuromuscular Disorders, 2007, 17, 349-350.	0.3	9
137	Interventions for the prevention and treatment of pes cavus. The Cochrane Library, 2007, , CD006154.	1.5	25
138	Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Annals of Neurology, 2007, 62, 422-426.	2.8	29
139	Spinal muscular atrophy type 1: Is long-term mechanical ventilation ethical?. Journal of Paediatrics and Child Health, 2007, 43, 237-242.	0.4	30
140	Physician attitudes towards ventilatory support for spinal muscular atrophy type 1 in Australasia. Journal of Paediatrics and Child Health, 2007, 43, 790-794.	0.4	30
141	Guillain-Barre syndrome in childhood. Journal of Paediatrics and Child Health, 2005, 41, 237-241.	0.4	66
142	CMTX mimicking childhood chronic inflammatory demyelinating neuropathy with tremor. Muscle and Nerve, 2005, 31, 528-530.	1.0	31
143	Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clinic Proceedings, 2003, 78, 858-868.	1.4	15
144	Anterior horn cell disease and olivopontocerebellar hypoplasia. Pediatric Neurology, 2000, 23, 180-184.	1.0	28

#	Article	IF	Citations
145	Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscular Disorders, 2000, 10, 398-406.	0.3	87